Fiche publication
Date publication
mars 2026
Journal
British journal of pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DESAUBRY Laurent
,
Dr NEBIGIL-DESAUBRY Canan
Tous les auteurs :
Audebrand A, Brogi S, Tezeren M, Tafi A, Ocak OH, Koyuncu H, Tetko I, Désaubry L, Nebigil CG
Lien Pubmed
Résumé
Anthracycline-induced cardiotoxicity, particularly from doxorubicin, remains a major limitation in cancer therapy, contributing to heart failure and long-term morbidity. Prokineticin receptor-1 (PKR), involved in cardiomyocyte survival and anti-fibrotic signalling, represents a promising therapeutic target. This study evaluated the cardioprotective potential of IS39, a novel non-peptide PKR agonist, in models of doxorubicin-induced cardiac injury.
Mots clés
chemoresistance, doxorubicin, hypoxia, prokineticin 2, reactive oxygen species
Référence
Br J Pharmacol. 2026 03 20;:
